SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Hadar Edelman-Klapper  ¹     Keren Masha Rabinowitz     Eran Zittan  ²     Ariella Bar Gil Shitrit  ³     Idan Goren     Irit Avni-Biron     Jacob E. Ollech     Lev Lichtenstein  ⁴     Hagar Banai-Eran     Henit Yanai     Yifat Snir     Maor H. Pauker     Adi Friedenberg     Adva Levy-Barda     Arie Segal  ⁵     Yelena Broitman     Eran Maoz  ⁶     Baruch Ovadia  ⁷     Maya Aharoni Golan     Eyal Shachar  ⁸     Shomron Ben-Horin     Michal Mor     Haim Ben Zvi     Tsachi-Tsadok Perets     Rami Eliakim     Revital Barkan     Michal Navon     Meital Gal-Tanamy  ⁹     Natalia T. Freund     Sophy Goren     Dani Cohen     Iris Dotan    
¹ Rabin Medical Center, Petah Tikva, Israel
² Emek Medical Center, Afula, Israel
³ Shaare Zedek Medical Center, Jerusalem, Israel
⁴ Clalit Health Services, Petah Tikva, Israel
⁵ Soroka University Medical Center, Beer-Sheva, Israel
⁶ Clalit Health Services, Tel Aviv, Israel
⁷ Hillel Yaffe Medical Center, Hadera, Israel
⁸ Tel Aviv University, Tel Aviv, Israel
⁹ Bar-Ilan University, Safed, Israel

Session
Covid-19 in IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)